Navigation Links
Response Genetics Announces $4 Million Private Placement
Date:7/22/2009

LOS ANGELES, July 22 /PRNewswire-FirstCall/ -- Response Genetics, Inc. (Nasdaq: RGDX) announced today that it has entered into a purchase agreement with certain funds managed by Lansdowne Partners Limited Partnership to raise approximately $4 million from the private placement of 3,057,907 newly issued shares of its common stock, at a purchase price of $1.30 per share. The closing of the sale of the shares occurred simultaneously with the signing of the purchase agreement on Wednesday, July 22, 2009.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from the registration requirements. Response Genetics, Inc. has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issued in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy Response Genetics, Inc.'s common stock.

About Response Genetics, Inc.

Response Genetics, Inc. ("RGI") (the "Company") (Nasdaq: RGDX) is focused on the development and sale of molecular diagnostic tests for cancer. RGI's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, RGI generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to successfully consummate the transactions contemplated by a purchase agreement or to successfully file a registration statement with the SEC, and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.


'/>"/>
SOURCE Response Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Covance to Sell Its Interactive Voice and Web Response Services and Enter Into a Multi-Year Marketing Agreement with Phase Forward
2. avVaa World Health Care Products, Inc. Announces Engagement of Koeppel Direct for their DRTV-Direct Response Television Media Buying Campaign
3. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
4. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
5. Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohns Patients
6. Amylin Issues Statement in Response to Carl Icahn
7. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
8. Drug Interaction Tool Offered Free in Response to Increasing At-Home Deaths From Medication Errors
9. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
10. Strengthening Forensic Toxicology in the United States: The American Board of Forensic Toxicology Response to the National Academy of Sciences Recommendations
11. Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... China , Feb. 4, 2016 Beike ... and various medical institutions attended a ceremony in late ... integrative, personalized cell therapy in 2016. ... "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" was ... Regional Cell Production Center, both subsidiaries of Beike Biotechnology ...
(Date:2/4/2016)... Columbia and MENLO PARK, Calif. ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused ... announced that it will present at the 18 th ... February 8, 2016 at 10:00 a.m. EST in ... , DelMar,s president and CEO, will provide an update on ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
(Date:2/4/2016)... BEIJING , Feb. 4, 2016 Sinovac ... ), a leading provider of biopharmaceutical products in ... committee of its board of directors received on February ... 3, 2016, from a consortium comprised of PKU V-Ming ... Sinobioway Biomedicine Co., Ltd., CICC Qianhai Development ( ...
Breaking Biology Technology:
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
(Date:1/13/2016)... 13, 2016 ... of the  "India Biometrics Authentication & ... (2015-2020)"  report to their offering.  ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ...
Breaking Biology News(10 mins):